GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
P

Panacea Life Sciences Holdings PLSH · USD

Health Care · US listing · 🇺🇸 United States

Compare

0.07

—

Close of 6 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2023

Revenue

$2.4m

FY2016FY2023

Net income

−$8.0m

FY2016FY2023

Free cash flow

−$1.6m

FY2016FY2023

Shareholders' equity

−$8.3m

FY2016FY2023

Income statement

Fiscal years

FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue$2.4m$1.6m$2.1m$2.1m$345,680———
Research and development————$22,100$300,000$356,076$369,300
Operating income−$5.5m−$5.7m−$5.5m−$6.0m−$10.9m−$2.4m−$2.1m−$1.6m
Net income−$8.0m−$9.1m−$4.8m−$9.5m−$9.7m−$4.3m−$3.9m−$1.6m
Diluted earnings per share-0.45-0.61-0.32-4.70-6.19-19.48-24.66-18.68

Balance sheet

At each fiscal year end

FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assets$18.0m$19.5m$23.8m$71,268$9.8m$14,290$172,673$2.1m
Cash and short-term investments———————$1.1m
Total liabilities$26.3m$21.6m$16.7m$5.1m$6.1m$3.4m$2.4m$625,000
Debt$3.6m$3.6m$3.3m$205,166$100,000$100,000——
Shareholders' equity−$8.3m−$2.1m$7.1m−$5.0m$3.7m−$3.4m−$2.2m$1.5m
Shares outstanding18m15m15m2m2m0m0m0m

Cash flow

Fiscal years

FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations−$1.5m−$2.4m−$3.9m−$7.6m−$3.9m−$465,755−$1.2m−$891,000
Capital spending−$65,322−$243,804−$162,946−$3.2m−$7.0m———
Free cash flow−$1.6m−$2.6m−$4.1m−$10.8m−$10.9m−$465,755−$1.2m−$891,000

Latest quarters

By quarter end

Sept 2025Jun 2025Mar 2025Sept 2024Jun 2024Mar 2024Dec 2023Sept 2023
Revenue$49,767$215,129$595,883$948,970$1.2m$1.1m$960,496$347,851
Operating income−$169,880−$717,034−$492,820−$665,487−$1.0m−$1.1m−$1.8m−$1.4m
Net income−$183,762$973,416−$3,325−$1.1m−$1.5m−$1.4m−$2.2m−$2.2m
Diluted earnings per share-0.010.05-0.00-0.05-0.07-0.08-0.13-0.12
Cash from operations−$1.0m———————
Total assets$4.0m$6.8m$8.8m$16.4m$17.0m$17.4m$18.0m$18.7m
Debt——$3.1m$3.6m$3.6m$3.6m$3.6m$3.6m
Shareholders' equity$3.8m−$9.9m−$10.5m−$12.2m−$11.1m−$9.6m−$8.3m−$6.1m

Growth per year

Compound annual rate

3 years5 years10 years
Revenue4.8%——
Operating income-2.5%17.9%—
Net income-5.4%13.1%—

Average margins

Over each period

1 year3 years5 years10 years
Operating margin-279.1%-279.0%——
Net margin-427.7%-385.6%——

Share price return

Finished calendar years

2025202420232022
Return932%798%355%408%

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years.

  • 28-to-1 reverse split · 28 Oct 2021
  • 8-to-1 reverse split · 11 Mar 2019
  • 29.5849-to-1 reverse split · 22 Mar 2016

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.